

## University of Groningen

### Therapeutic drug monitoring

Pranger, Anna Diewerke

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*  
2018

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Pranger, A. D. (2018). *Therapeutic drug monitoring: How to improve moxifloxacin exposure in tuberculosis patients*. [Thesis fully internal (DIV), University of Groningen]. Rijksuniversiteit Groningen.

**Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

**Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

# Therapeutic drug monitoring: how to improve moxifloxacin exposure in tuberculosis patients

Arianna Pranger

Pranger, A.D.

**Therapeutic drug monitoring: how to improve moxifloxacin exposure in tuberculosis patients**

Thesis, University of Groningen, Groningen, the Netherlands

The work described in this thesis was performed at the department of Clinical Pharmacy and Pharmacology of the University Medical Center Groningen.

Publication of this thesis was financially supported by the Graduate School of Medical Sciences and the University Medical Center Groningen.

<b>Cover image</b>	Marijke van Zuilten, <a href="http://marijkeengerjannevanzuilten.nl">http://marijkeengerjannevanzuilten.nl</a>
<b>Lay-out</b>	Jeffrey Grashof, Gildeprint & Arianna Pranger
<b>Printed by</b>	Gildeprint

ISBN: 978-94-034-0987-0 (printed version)

ISBN: 978-94-034-0986-3 (digital version)

© A.D. Pranger 2018

Copyright of the published articles is with the corresponding journal or otherwise with the author. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing from the author or the copyright-owing journal.



**rijksuniversiteit  
 groningen**

# **Therapeutic drug monitoring: how to improve moxifloxacin exposure in tuberculosis patients**

## **Proefschrift**

ter verkrijging van de graad van doctor aan de  
 Rijksuniversiteit Groningen  
 op gezag van de  
 rector magnificus prof. dr. E. Sterken  
 en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

woensdag 31 oktober 2018 om 11.00 uur

door

**Anna Diewerke Pranger**

geboren op 26 november 1985  
 te Leeuwarden

**Promotores**

Prof. dr. J.G.W. Kosterink  
Prof. dr. T.S. van der Werf  
Em. prof. dr. D.R.A. Uges

**Copromotor**

Dr. J.W.C. Alffenaar

**Beoordelingscommissie**

Prof. dr. F.G.J. Cobelens  
Prof. dr. H.J. Guchelaar  
Prof. dr. H.A.M. Kerstjens

**Paranimfen**

N.M. Pranger, MSc

Dr. K.C.M. van der Elst

Voor opa & oma, pake & beppe ♥

# Contents

<b>Chapter 1</b>	<b>9</b>
Introduction and scope of thesis	
<b>Chapter 2a</b>	<b>21</b>
Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach	
<b>Chapter 2b</b>	<b>103</b>
The role of fluoroquinolones in the treatment of tuberculosis anno 2018	
<b>Chapter 3</b>	<b>123</b>
Determination of moxifloxacin in human plasma, plasma ultrafiltrate, and cerebrospinal fluid by a rapid and simple liquid chromatography-tandem mass spectrometry method	
<b>Chapter 4a</b>	<b>143</b>
Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience	
<b>Chapter 4b</b>	<b>161</b>
Low moxifloxacin exposure in male tuberculosis patients and the need for monitoring in early stages of treatment	
<b>Chapter 4c</b>	<b>179</b>
Rifampicin and moxifloxacin for tuberculous meningitis	
<b>Chapter 5</b>	<b>183</b>
Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis	
<b>Chapter 6</b>	<b>199</b>
Thin layer chromatography to support therapeutic drug monitoring of moxifloxacin in resource-limited settings	
<b>Chapter 7</b>	<b>217</b>
General discussion and future perspectives	
<b>Chapter 8</b>	<b>231</b>
Summary	
<b>Epilogue</b>	
Nederlandse samenvatting	<b>243</b>
Dankwoord	<b>252</b>
About the author	<b>258</b>



